今年7月22日,傳來(lái)了一個(gè)好消息:輝瑞(Pfizer)及其合作伙伴BioNTech將開始在非洲生產(chǎn)新冠疫苗,目的正是供應(yīng)非洲市場(chǎng)。這個(gè)發(fā)展令人歡欣鼓舞。非洲人口占全球人口的17%以上,但根據(jù)世界衛(wèi)生組織(World Health Organization)的數(shù)據(jù),到目前為止,非洲獲得的新冠疫苗數(shù)量只占全球供應(yīng)量的1.7%。根據(jù)收集地方政府信息的組織Our World in Data的數(shù)據(jù),截至7月20日,非洲只有3%的人口注射了一劑或兩劑新冠疫苗。
在輝瑞宣布這一消息之際,國(guó)際形勢(shì)正處于非常緊迫的狀態(tài)。盡管非洲國(guó)家在新冠疫情的早期階段管理相對(duì)良好,但在過(guò)去9周內(nèi),其新增新冠肺炎病例數(shù)目出現(xiàn)了激增——德爾塔變種等傳染性更強(qiáng)的病毒株在非洲的傳播難辭其咎。非洲大陸北部以及南部,尤其是利比亞和突尼斯、博茨瓦納和納米比亞,都出現(xiàn)了病例激增的情況。在過(guò)去7天里,這些國(guó)家平均每天每百萬(wàn)人中就有300多例新病例。
據(jù)世界衛(wèi)生組織的數(shù)據(jù),上周整個(gè)非洲大陸的新增病例略有下降(下降了1.7%,至28.2萬(wàn)人),但這在很大程度上歸功于南非情況的改善。除南非外,整個(gè)非洲大陸的新增病例在過(guò)去一周內(nèi)增加了18%,比之前的峰值高出80%。
此外,有21個(gè)非洲國(guó)家在過(guò)去兩周內(nèi)的新增病例數(shù)量分別增長(zhǎng)了20%以上。
世界衛(wèi)生組織非洲區(qū)域主任馬希迪索?莫蒂博士在7月23日發(fā)表的一份聲明中說(shuō):“不要抱有任何僥幸心理,非洲的第三波疫情絕對(duì)尚未結(jié)束。許多國(guó)家的風(fēng)險(xiǎn)指數(shù)仍然處于峰值?!?/p>
與此同時(shí),新冠疫苗在非洲的推廣卻處于相當(dāng)早期的階段。7個(gè)非洲國(guó)家對(duì)其人口提供至少一種新冠疫苗的比例不到1%;另外23個(gè)國(guó)家的疫苗提供比例也不及5%。毛里求斯是接種疫苗最多的非洲島國(guó),有47.82%的人口接種了疫苗;摩洛哥緊隨其后,約31%的人口已經(jīng)注射了至少一劑疫苗。
目前的問(wèn)題不是需求,而是供應(yīng)。雖然將有疫苗送入非洲(6000萬(wàn)疫苗將在未來(lái)幾周抵達(dá)非洲國(guó)家),但這還不夠及時(shí)。世界衛(wèi)生組織報(bào)告稱,到今年年底,新冠肺炎疫苗實(shí)施計(jì)劃(COVAX)將向非洲大陸提供5億多劑疫苗。
輝瑞與BioNTech將與南非公司Biovac合作,在非洲生產(chǎn)疫苗,但是要到2022年才會(huì)投產(chǎn)。一旦全面投產(chǎn),這一項(xiàng)目每年將生產(chǎn)超過(guò)1億支疫苗。
7月22日,輝瑞的首席執(zhí)行官艾伯樂(lè)(Albert Bourla)在談到這一計(jì)劃時(shí)稱:“從第一天起,我們的目標(biāo)就是為世界各地的每個(gè)人提供公平、公正合理的新冠疫苗。”
南非的Biovac公司首席執(zhí)行官莫雷娜?馬克阿納博士則表示,這一進(jìn)展是“在抗擊這一悲劇性的全球疫情的斗爭(zhēng)當(dāng)中,在加強(qiáng)獲得疫苗的可持續(xù)渠道方面邁出的關(guān)鍵一步”。
美國(guó)樂(lè)施會(huì)(Oxfam America)的高級(jí)宣傳經(jīng)理、人民疫苗聯(lián)盟(People’s Vaccine Alliance)的發(fā)言人羅比?西爾弗曼認(rèn)為輝瑞公司的計(jì)劃是“好消息”。但他指出,就現(xiàn)如今輝瑞的絕大多數(shù)疫苗分發(fā)的去向而言,“這根本不夠”。(財(cái)富中文網(wǎng))
編譯:楊二一
今年7月22日,傳來(lái)了一個(gè)好消息:輝瑞(Pfizer)及其合作伙伴BioNTech將開始在非洲生產(chǎn)新冠疫苗,目的正是供應(yīng)非洲市場(chǎng)。這個(gè)發(fā)展令人歡欣鼓舞。非洲人口占全球人口的17%以上,但根據(jù)世界衛(wèi)生組織(World Health Organization)的數(shù)據(jù),到目前為止,非洲獲得的新冠疫苗數(shù)量只占全球供應(yīng)量的1.7%。根據(jù)收集地方政府信息的組織Our World in Data的數(shù)據(jù),截至7月20日,非洲只有3%的人口注射了一劑或兩劑新冠疫苗。
在輝瑞宣布這一消息之際,國(guó)際形勢(shì)正處于非常緊迫的狀態(tài)。盡管非洲國(guó)家在新冠疫情的早期階段管理相對(duì)良好,但在過(guò)去9周內(nèi),其新增新冠肺炎病例數(shù)目出現(xiàn)了激增——德爾塔變種等傳染性更強(qiáng)的病毒株在非洲的傳播難辭其咎。非洲大陸北部以及南部,尤其是利比亞和突尼斯、博茨瓦納和納米比亞,都出現(xiàn)了病例激增的情況。在過(guò)去7天里,這些國(guó)家平均每天每百萬(wàn)人中就有300多例新病例。
據(jù)世界衛(wèi)生組織的數(shù)據(jù),上周整個(gè)非洲大陸的新增病例略有下降(下降了1.7%,至28.2萬(wàn)人),但這在很大程度上歸功于南非情況的改善。除南非外,整個(gè)非洲大陸的新增病例在過(guò)去一周內(nèi)增加了18%,比之前的峰值高出80%。
此外,有21個(gè)非洲國(guó)家在過(guò)去兩周內(nèi)的新增病例數(shù)量分別增長(zhǎng)了20%以上。
世界衛(wèi)生組織非洲區(qū)域主任馬希迪索?莫蒂博士在7月23日發(fā)表的一份聲明中說(shuō):“不要抱有任何僥幸心理,非洲的第三波疫情絕對(duì)尚未結(jié)束。許多國(guó)家的風(fēng)險(xiǎn)指數(shù)仍然處于峰值?!?/p>
與此同時(shí),新冠疫苗在非洲的推廣卻處于相當(dāng)早期的階段。7個(gè)非洲國(guó)家對(duì)其人口提供至少一種新冠疫苗的比例不到1%;另外23個(gè)國(guó)家的疫苗提供比例也不及5%。毛里求斯是接種疫苗最多的非洲島國(guó),有47.82%的人口接種了疫苗;摩洛哥緊隨其后,約31%的人口已經(jīng)注射了至少一劑疫苗。
目前的問(wèn)題不是需求,而是供應(yīng)。雖然將有疫苗送入非洲(6000萬(wàn)疫苗將在未來(lái)幾周抵達(dá)非洲國(guó)家),但這還不夠及時(shí)。世界衛(wèi)生組織報(bào)告稱,到今年年底,新冠肺炎疫苗實(shí)施計(jì)劃(COVAX)將向非洲大陸提供5億多劑疫苗。
輝瑞與BioNTech將與南非公司Biovac合作,在非洲生產(chǎn)疫苗,但是要到2022年才會(huì)投產(chǎn)。一旦全面投產(chǎn),這一項(xiàng)目每年將生產(chǎn)超過(guò)1億支疫苗。
7月22日,輝瑞的首席執(zhí)行官艾伯樂(lè)(Albert Bourla)在談到這一計(jì)劃時(shí)稱:“從第一天起,我們的目標(biāo)就是為世界各地的每個(gè)人提供公平、公正合理的新冠疫苗。”
南非的Biovac公司首席執(zhí)行官莫雷娜?馬克阿納博士則表示,這一進(jìn)展是“在抗擊這一悲劇性的全球疫情的斗爭(zhēng)當(dāng)中,在加強(qiáng)獲得疫苗的可持續(xù)渠道方面邁出的關(guān)鍵一步”。
美國(guó)樂(lè)施會(huì)(Oxfam America)的高級(jí)宣傳經(jīng)理、人民疫苗聯(lián)盟(People’s Vaccine Alliance)的發(fā)言人羅比?西爾弗曼認(rèn)為輝瑞公司的計(jì)劃是“好消息”。但他指出,就現(xiàn)如今輝瑞的絕大多數(shù)疫苗分發(fā)的去向而言,“這根本不夠”。(財(cái)富中文網(wǎng))
編譯:楊二一
On July 22, brought the good news that Pfizer and its partner BioNTech would start manufacturing its COVID-19 vaccines in Africa, for Africa. That’s a welcome development in a part of the world that is home to more than 17% of the planet’s population but so far, has received only 1.7% of the global supply of coronavirus vaccines according to the World Health Organization. Through July 20, just 3% of Africa’s population has received at least one COVID shot according to Our World in Data, which collects information from local governments.
Pfizer’s announcement arrived at a time when the urgency couldn’t be clearer. After managing the early phases of the pandemic relatively well, African countries for the past nine weeks have been battling surging new COVID case numbers due to the spread of more transmissible virus strains like the Delta variant. Cases have exploded in the North and South of the continent, particularly in Libya and Tunisia, and Botswana and Namibia respectively; each of those countries has an average of more than 300 new cases per day per million people for the past seven days.
While the number of new cases dipped slightly last week for the whole continent—down by 1.7% to 282,000 according to the World Health Organization—that is largely due to the improving situation in South Africa. Excluding South Africa, numbers across the continent increased 18% over the past week, and are 80% higher than what they were at the previous peak.
According to the WHO, 21 African countries have seen cases rise by over 20% for each of the past two weeks.
“Be under no illusions, Africa’s third wave is absolutely not over,” said Dr. Matshidiso Moeti, WHO’s Regional Director for Africa, in a statement issued on July 23. “Many countries are still at peak risk.”
The vaccine rollout, meanwhile, is of course in the very early stages. Seven African countries have yet to reach 1% of their populations with at least one COVID vaccine; another 23 are below 5%. The island of Mauritius is furthest along with 47.82% of its population vaccinated; Morocco comes next with about 31% of its population having gotten one shot.
The problem at the moment is not demand, but supply. While more vaccines are coming—60 million vaccines are due to arrive for African countries in the coming weeks—it’s not soon enough. The WHO reports COVAX will have delivered more than 500 million doses to the continent by the end of the year.
The African-manufactured Pfizer and BioNTech vaccines, which will be produced in collaboration with the South African firm Biovac, won’t roll off the lines until 2022. The effort will produce more than 100 million vaccines per year once it’s operating at full capacity.
“From day one, our goal has been to provide fair and equitable access of the Pfizer-BioNTech COVID-19 Vaccine to everyone, everywhere,” Pfizer CEO Albert Bourla said about the effort on July 22.
Dr. Morena Makhoana, CEO of South Africa’s Biovac described the development as “a critical step forward in strengthening sustainable access to a vaccine in the fight against this tragic, worldwide pandemic.”
Robbie Silverman, Oxfam America’s Senior Advocacy Manager and spokesperson for the People’s Vaccine Alliance, called Pfizer’s announcement “good news,” but noting where the vast majority of the company’s vaccines had been distributed so far added, “It is simply not enough.”